Their efficacy was initially observed in the CREDENCE trial, which primarily evaluated the reno-protective effect of SGLT-2 inhibitors, and where canagliflozin was found to significantly reduce major cardiovascular and renal events in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.